To test whether SCFA supplementation resembled HDAC inhibition, we compared the treatment of CRC cells with increasing levels of propionate, butyrate and trichostatin A (TSA), a potent HDAC inhibitor. Here, HDAC9 is linked to colorectal carcinoma.